Harrow’s 2025 Close-Up: Cash Flows, Growth Milestones, and a Bold 2026 Revenue Forecast

The ophthalmic-disease platform Harrow (HROW) reported its fourth-quarter and full-year results for 2025 alongside a 2026 guidance deck that tilts toward a higher revenue trajectory and a more robust cash-generating engine. Revenue tallies were solid: $89.1 million for Q4 and $272.3 million for the full year, marking respectable year-over-year increases of 33% and 36%, respectively. On the profitability line, GAAP net income for Q4 stood at $6.6 million, while the company posted a full-year net loss of $5.1 million. Adjusted EBITDA reached $24.2 million in Q4 and $61.9 million for 2025. Cash generation showed real progress, with $43.9 million of operating cash flow in 2025 and year-end cash and equivalents of $72.9 million. The 2026 revenue forecast sits between $350 million and $365 million, with a split that suggests a meaningful ramp in the first half followed by continued momentum. EBITDA guidance for 2026 comes in between $80 million and $100 million.

Key financials at a glance

• Q4 revenue: $89.1 million; full-year revenue: $272.3 million (both up meaningfully year over year).
• GAAP net income in Q4: $6.6 million; full-year net loss: $5.1 million.
• Adjusted EBITDA: $24.2 million in Q4; $61.9 million for 2025.
• Operating cash flow: $43.9 million in 2025; cash and cash equivalents: $72.9 million as of December 31, 2025.
• 2026 revenue forecast: $350–$365 million; 2026 Adjusted EBITDA: $80–$100 million.

From quarterly cadence to growth cadence

Harrow’s narrative centers on translating product traction into a scalable commercial engine. The company flags continued ramp in its key ophthalmic platforms—VEVYE, IHEEZO, and TRIESENCE—while signaling a broader push to expand the office-based footprint for IHEEZO and to accelerate its development pipeline. Management frames 2026 as stage-setting for a longer arc toward a goal of more than $250 million in quarterly revenue by the end of 2027, a target that implicitly relies on a persistent combination of product adoption, sales force expansion, and operational discipline.

Guidance in focus: 2026 revenue forecast and EBITDA trajectory

The 2026 revenue forecast of $350 million to $365 million implies upside potential relative to 2025 results—an implied growth rate in the low-to-mid 30s percent range on a year-over-year basis, depending on quarterly cadence and product uptake. The 2026 Adjusted EBITDA guidance of $80 million to $100 million signals a more cash-flow-focused improvement even as the company continues to invest in its growth engine. Investors will likely compare these figures against the EPS trajectory implied by the mix of GAAP net income, share count, and any non-cash adjustments embedded in EBITDA reconciliation.

Implications for HROW and peers

With Harrow steering toward a bigger, more diversified product slate and a stronger commercial footprint, the story shifts from a quarterly flush of revenue to a longer, steadier stream of cash generation. For the equity narrative, the key questions will be: Does the 2026 revenue forecast translate into meaningful EPS momentum on a per-share basis? How durable is the revenue mix as VEVYE, IHEEZO, and TRIESENCE scale? And how quickly can Harrow convert pipeline opportunities into repeated, outsized operating cash flows? In the sector, peers with similar product suites and office-based adoption curves may watch Harrow’s cadence closely, particularly the pace of sales-force expansion and how the company balances R&D investment with profitability metrics like EPS consensus and EBITDA margins.

Operational takeaways: One Harrow and the development roadmap

The press materials emphasize a unified operating plan—“One Harrow”—that aims to coordinate commercial execution, development efforts, and market access. The pipeline mention—late-stage assets such as G-MELT (formerly MELT-300) and YOCHIL (formerly MELT-210)—highlights a strategy to extend a high-growth trajectory beyond current products. In practice, this means the company is betting on a productization cycle where regulatory milestones and field-adoption rates jointly shape the revenue and EBITDA path. A healthy cash balance and positive operating cash flow in 2025 bolster the balance sheet as Harrow advances this plan.

Bottom line: A disciplined growth story with a healthy cash spine

HROW’s reported results echo a familiar pattern: solid top-line growth, a transition from GAAP net income volatility to a more predictable EBITDA-driven profitability pathway, and a clear push toward a multi-year revenue trajectory. The 2026 revenue forecast and EBITDA guidance provide a framework for investor discussion—will management sustain the cadence into late 2020s, and how will the product mix, international expansion (if any), and operational leverage interact with the expectations baked into the EPS consensus? For now, Harrow trades on a plan as much as on a quarter’s performance, with the ticker symbol HROW perched above a long horizon of potential product launches and scaled adoption.

For readers tracking earnings dynamics, the story this season centers on the interplay between revenue forecast optimism and EPS trajectory, with attention to earnings surprise potential versus consensus expectations. The focus on 2026 guidance, EBITDA progression, and the cash-generation narrative are likely to influence how analysts model the stock in coming months.